Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV
Article Sidebar
Main Article Content
Abstract
Background: Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis.
Methods: Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured.
Results: Median age at week 0 was 39 years, CD4+ T cell count 496 cells/mm3, HIV RNA levels <20 copies/mL. FMT was safe and well-tolerated. Alpha diversity increased in 4 participants from weeks 0 to 6, including the 3 with the lowest alpha diversity at week 0. At week 26, alpha diversity more closely resembled week 0 than week 6 in these 4 participants. Metagenomic analysis showed no consistent changes across all participants. One participant had high gut permeability and inflammation biomarker levels and low alpha diversity that improved between weeks 0 and 6 with a shift in distribution.
Conclusions: Weekly FMT was safe and well-tolerated. Alpha diversity increased in participants with the lowest baseline alpha diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.
ClinicalTrials.gov Identifier: NCT03329560
Downloads
Article Details
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Utay NS, Overton ET. Immune activation and inflammation in people with HIV: Challenging targets. J Infect Dis. 2019. doi: 10.1093/infdis/jiz351. PubMed PMID:31282534.
2. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655-66. Epub 2012/08/14. doi: 10.1038/nrmicro2848. PubMed PMID: 22886237.
3. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780-90. Epub 2011/01/22. doi: 10.1093/infdis/jiq118. PubMed PMID: 21252259; PMCID: Pmc3071127.
4. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248-59. Epub 2014/05/06. doi: 10.1093/infdis/jiu254. PubMed PMID: 24795473; PMCID: PMC4192039.
5. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228-38. Epub 2014/04/24. doi: 10.1093/infdis/jiu238. PubMed PMID: 24755434; PMCID: PMC4192038.
6. Vujkovic-Cvijin I, Somsouk M. HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. Curr HIV/AIDS Rep. 2019;16(3):204-13. Epub 2019/05/01. doi: 10.1007/s11904-019-00441-w. PubMed PMID: 31037552; PMCID: PMC6579656.
7. Neff CP, Krueger O, Xiong K, Arif S, Nusbacher N, Schneider JM, Cunningham AW, Armstrong A, Li S, McCarter MD, Campbell TB, Lozupone CA, Palmer BE. Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals. EBioMedicine. 2018;30:192-202. Epub 2018/04/14. doi: 10.1016/j.ebiom.2018.03.024. PubMed PMID: 29650491; PMCID: PMC5952409.
8. Li SX, Sen S, Schneider JM, Xiong KN, Nusbacher NM, Moreno-Huizar N, Shaffer M, Armstrong AJS, Severs E, Kuhn K, Neff CP, McCarter M, Campbell T, Lozupone CA, Palmer BE. Gut microbiota from high-risk men who have sex with men drive immune activation in gnotobiotic mice and in vitro HIV infection. PLoS Pathog.2019;15(4):e1007611. Epub 2019/04/05. doi: 10.1371/journal.ppat.1007611. PubMed PMID: 30947289; PMCID: PMC6448819.
9. Noguera-Julian M, Rocafort M, Guillen Y, Rivera J, Casadella M, Nowak P, Hildebrand F, Zeller G, Parera M, Bellido R, Rodriguez C, Carrillo J, Mothe B, Coll J, Bravo I, Estany C, Herrero C, Saz J, Sirera G, Torrela A, Navarro J, Crespo M, Brander C, Negredo E, Blanco J, Guarner F, Calle ML, Bork P, Sonnerborg A, Clotet B, Paredes R. Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine. 2016;5:135-46. Epub 2016/04/15. doi: 10.1016/j.ebiom.2016.01.032. PubMed PMID: 27077120; PMCID: PMC4816837.
10. Kelley CF, Kraft CS, de Man TJ, Duphare C, Lee HW, Yang J, Easley KA, Tharp GK, Mulligan MJ, Sullivan PS, Bosinger SE, Amara RR. The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention. Mucosal Immunol. 2017;10(4):996-1007. Epub 2016/11/17. doi: 10.1038/mi.2016.97. PubMed PMID: 27848950; PMCID: PMC5433931.
11. Armstrong AJS, Shaffer M, Nusbacher NM, Griesmer C, Fiorillo S, Schneider JM, Preston Neff C, Li SX, Fontenot AP, Campbell T, Palmer BE, Lozupone CA. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiome.
2018;6(1):198. Epub 2018/11/07. doi: 10.1186/s40168-018-0580-7. PubMed PMID: 30396369; PMCID: PMC6219090.
12. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. Epub 2018/02/21. doi: 10.1093/cid/cix1085. PubMed PMID: 29462280; PMCID: PMC6018983.
13. Vujkovic-Cvijin I, Rutishauser RL, Pao M, Hunt PW, Lynch SV, McCune JM, Somsouk M. Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes. 2017;8(5):440-50. Epub 2017/05/26. doi: 10.1080/19490976.2017.1334034. PubMed PMID: 28541799; PMCID: PMC5628639.
14. Ding X, Li Q, Li P, Zhang T, Cui B, Ji G, Lu X, Zhang F. Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis. Drug Saf. 2019;42(7):869-80. Epub 2019/04/12. doi: 10.1007/s40264-019-00809-2. PubMed PMID: 30972640.
15. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):102-9 e6. Epub 2015/04/11. doi: 10.1053/j.gastro.2015.04.001. PubMed PMID: 25857665.
16. Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One. 2018;13(11):e0205064. Epub 2018/11/06. doi: 10.1371/journal.pone.0205064. PubMed PMID: 30388112; PMCID: PMC6214502.
17. Glass RI, Noel J, Ando T, Fankhauser R, Belliot G, Mounts A, Parashar UD, Bresee JS, Monroe SS. The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis. 2000;181 Suppl 2:S254-61. Epub 2000/05/11. doi: 10.1086/315588. PubMed PMID: 10804134.
18. Ottesen A, Ramachandran P, Reed E, White JR, Hasan N, Subramanian P, Ryan G, Jarvis K, Grim C, Daquiqan N, Hanes D, Allard M, Colwell R, Brown E, Chen Y. Enrichment dynamics of Listeria monocytogenes and the associated microbiome from naturally contaminated ice cream linked to a listeriosis outbreak. BMC Microbiol.2016;16(1):275. Epub 2016/11/18. doi: 10.1186/s12866-016-0894-1. PubMed PMID: 27852235; PMCID: PMC5112668.
19. Ponnusamy D, Kozlova EV, Sha J, Erova TE, Azar SR, Fitts EC, Kirtley ML, Tiner BL, Andersson JA, Grim CJ, Isom RP, Hasan NA, Colwell RR, Chopra AK. Cross-talk among flesh-eating Aeromonas hydrophila strains in mixed infection leading to necrotizing fasciitis. Proc Natl Acad Sci U S A. 2016;113(3):722-7. Epub 2016/01/07. doi: 10.1073/pnas.1523817113. PubMed PMID: 26733683; PMCID: PMC4725515.
20. Hasan NA, Young BA, Minard-Smith AT, Saeed K, Li H, Heizer EM, McMillan NJ, Isom R, Abdullah AS, Bornman DM, Faith SA, Choi SY, Dickens ML, Cebula TA, Colwell RR. Microbial community profiling of human saliva using shotgun metagenomic sequencing. PLoS One. 2014;9(5):e97699. Epub 2014/05/23. doi: 10.1371/journal.pone.0097699. PubMed PMID: 24846174; PMCID: PMC4028220.
21. Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons SM, Larsen P, Shogan BD, Weiss S, Metcalf JL, Ursell LK, Vazquez-Baeza Y, Van Treuren W, Hasan NA, Gibson MK, Colwell R, Dantas G, Knight R, Gilbert
JA. Longitudinal analysis of microbial interaction between humans and the indoor environment. Science. 2014;345(6200):1048-52. Epub 2014/08/30. doi: 10.1126/science.1254529. PubMed PMID: 25170151; PMCID: PMC4337996.
22. Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics. 2015;31(10):1674-6. Epub 2015/01/23. doi: 10.1093/bioinformatics/btv033. PubMed PMID: 25609793.
23. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068-9. Epub 2014/03/20. doi: 10.1093/bioinformatics/btu153. PubMed PMID: 24642063.
24. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ, Louis P. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J. 2014;8(6):1323-35. Epub 2014/02/21. doi: 10.1038/ismej.2014.14. PubMed PMID: 24553467; PMCID: PMC4030238.
25. Fu X, Liu Z, Zhu C, Mou H, Kong Q. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr. 2019;59(sup1):S130-S52. Epub 2018/12/26. doi: 10.1080/10408398.2018.1542587. PubMed PMID: 30580556.
26. Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol.2017;101(1):47-64. Epub 2016/11/27. doi: 10.1007/s00253-016-8006-6. PubMed PMID: 27888332; PMCID: PMC5203956.
27. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306(4):G310-9. Epub 2013/11/29. doi: 10.1152/ajpgi.00282.2013. PubMed PMID: 24284963; PMCID: PMC3920123.
28. Staley C, Kaiser T, Vaughn BP, Graiziger CT, Hamilton MJ, Rehman TU, Song K, Khoruts A, Sadowsky MJ. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome. 2018;6(1):166. Epub 2018/09/20. doi: 10.1186/s40168-018-0549-6. PubMed PMID: 30227892; PMCID: PMC6145197.
29. Zou M, Jie Z, Cui B, Wang H, Feng Q, Zou Y, Zhang X, Yang H, Wang J, Zhang F, Jia H. Fecal microbiota transplantation results in bacterial strain displacement in patients with inflammatory bowel diseases. FEBS Open Bio. 2020;10(1):41-55. Epub 2019/10/18. doi: 10.1002/2211-5463.12744. PubMed PMID: 31622538; PMCID:PMC6943227.
30. Hirten RP, Grinspan A, Fu SC, Luo Y, Suarez-Farinas M, Rowland J, Contijoch EJ, Mogno I, Yang N, Luong T, Labrias PR, Peter I, Cho JH, Sands BE, Colombel JF, Faith JJ, Clemente JC. Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(6):969-79. Epub 2019/03/11. doi: 10.1093/ibd/izy398. PubMed PMID: 30852592; PMCID: PMC6499938.
31. DuPont HL, Jiang ZD, DuPont AW, Utay NS. Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation. Dig Dis Sci. 2020;65(3):741-56. Epub 2020/02/03. doi: 10.1007/s10620-020-06102-y. PubMed PMID: 32008133.
32. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, Tholey A, Fickenscher H, Seegert D, Rosenstiel P, Schreiber S. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2017;152(4):799-811 e7. Epub 2016/11/22. doi: 10.1053/j.gastro.2016.11.010. PubMed PMID: 27866880.
33. Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27-43. Epub 2012/03/01. doi: 10.4291/wjgp.v3.i1.27. PubMed PMID: 22368784; PMCID: PMC3284523.
34. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology. 2016;5(4):e73. Epub 2016/05/20. doi: 10.1038/cti.2016.17. PubMed PMID: 27195116; PMCID: PMC4855267.
35. Baktash A, Terveer EM, Zwittink RD, Hornung BVH, Corver J, Kuijper EJ, Smits WK. Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. Front Microbiol. 2018;9:1242. Epub 2018/06/28. doi: 10.3389/fmicb.2018.01242. PubMed PMID: 29946308; PMCID: PMC6005852.
36. Pruller F, Wagner J, Raggam RB, Hoenigl M, Kessler HH, Truschnig-Wilders M, Krause R. Automation of serum (1-->3)-beta-D-glucan testing allows reliable and rapid discrimination of patients with and without candidemia. Med Mycol. 2014;52(5):455-61. Epub 2014/06/08. doi: 10.1093/mmy/myu023. PubMed PMID: 24906361.
37. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 2011;204(1):154-63. Epub 2011/06/02. doi: 10.1093/infdis/jir214.PubMed PMID: 21628670; PMCID: PMC3105035.
38. Utay NS, Somasunderam A, Hinkle JE, Petschow BW, Detzel CJ, Somsouk M, Fichtenbaum CJ, Weaver EM, Shaw AL, Asmuth DM. Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. Pathog Immun. 2019;4(1):124-46. Epub 2019/05/30. doi: 10.20411/pai.v4i1.276. PubMed PMID: 31139758; PMCID: PMC6508431.
39. Ward-Kavanagh LK, Lin WW, Sedy JR, Ware CF. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity. 2016;44(5):1005-19. Epub 2016/05/19. doi: 10.1016/j.immuni.2016.04.019. PubMed PMID: 27192566; PMCID: PMC4882112.
40. Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, Wietgrefe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med. 2017;23(11):1271-6. Epub 2017/10/03. doi: 10.1038/nm.4411. PubMed PMID: 28967921; PMCID: PMC5831193.
41. Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9:2. Epub 2019/02/06. doi: 10.3389/fcimb.2019.00002. PubMed PMID: 30719428; PMCID: PMC6348388.